ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

OUTCOME OF THE TREATMENT OF BURKITT LYMPHOMA AT KING ABDUL-AZIZ MEDICAL CITY, RIYADH

AUTHORS:

Mohsen Alzahrani, Abdulrahman Alhadlaq, Abdulrahman Alqahtani, Faisal Alnaqa, Khalid Alotaibi, Mohammed Alrashed, Muath Alghamdi*

ABSTRACT:

Objective: To study the response of patients of Burkitt lymphoma to the first line regimen at King Abdul-Aziz Medical City in Riyadh, and to determine the 2-years survival rate. Methods: A retrospective cross-sectional study was preformed that included all patients diagnosed with Burkitt lymphoma from 1 January 2001 to 1 August 2017. SPSS version 20 software was used to analyze the data. The association between mortality rate and patients' characteristics, risk factors and complication was assessed. Fischer's exact test was used to detect significant values. Results: The study included thirteen adult patients with Burkitt lymphoma whom were treated with the first line regimen in King Abdul-Aziz Medical City, Riyadh. The variables that showed significant results were Bone marrow involvement with a P value of 0.014 and Tumor lysis syndrome with a P value of 0.045. Mortality rate in this study was 23% with fatalities occurred within the first two months of the treatment. Conclusion: Burkitt lymphoma is a disease of a good prognosis. The treatment regimen used for patients with Burkitt lymphoma in King Abdul-Aziz Medical City showed similar mortality rate as those recorded in other global studies. Tumor lysis syndrome and bone marrow involvement had a significant effect on mortality rate in this study. Keywords: Burkitt, Lymphoma, Outcome, Treatment

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.